Lipid-Based Nanocarriers in the Management of Pulmonary Complications in Cystic Fibrosis

Author:

Maheshwari Shubhrat1ORCID,Singh Aditya2

Affiliation:

1. Faculty of Pharmaceutical Sciences Rama University Mandhana, Bithoor Road, Kanpur, Uttar Pradesh, 209217, India

2. Department of Pharmacy, Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, 226026, India

Abstract

Abstract:: Code 35, the cystic fibrosis transmembrane conductance regulator (CFTR) causes respiratory failure, inflammation, and decreased airway mucociliary clearance. The absence of trustworthy preclinical models that replicate the anatomical, immunological, and bioelectrical characteristics of human CF lungs restricts the discovery of new therapies for the disease. Alternative carriers to liposomes, polymeric nanoparticles, and inorganic carriers include lipid-based nanocarriers (LBCs). Delivering medicines, nucleic acids, proteins, peptides, nutraceuticals, and cosmetics via LBCs has received more and more attention in recent years. Due to their simple production, physicochemical stability, and scalability, these nanocarriers have caught the attention of the industrial sector. Because of these qualities, LBCs are well suited for industrial manufacturing. Clinical trials are already being conducted on a number of LBC-containing items and are likely to swiftly grow in popularity. For commercial applications to produce enough formulations for clinical research, a large-scale manufacturing facility is necessary. The mainstay of treatment for CF, asthma, and chronic obstructive lung disease is the inhalation of corticosteroids and topical bronchodilators. These drugs are given through a metered-dose inhaler (MDI), a dry powder inhaler (DPI), a jet, or an ultrasonic nebulizer. Although the sheer number of gadgets may be overwhelming for patients and doctors, each has unique benefits.

Publisher

Bentham Science Publishers Ltd.

Subject

Pulmonary and Respiratory Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3